Missed bronchodilator medication treatments in respiratory therapy: frequency and underlying causes.
نویسندگان
چکیده
BACKGROUND In the context of increasing attention to medical errors, missed therapies have become a subject of focus both for optimizing clinical care and for assuring appropriate institutional performance during external review by accrediting bodies. Because the issue of missed treatments in respiratory therapy has received little attention to date, we undertook to describe the frequency and causes of missed respiratory therapy bronchodilator medication treatments at the Cleveland Clinic Hospital. METHODS Between August 2000 and August 2001, using a respiratory therapy management information system, we recorded the number of respiratory therapy bronchodilator medication treatments ordered and delivered (via small-volume nebulizer and metered-dose inhaler) and the reason(s) for each missed treatment. RESULTS Over the 12-month study interval 113,554 bronchodilator medication treatments (74,921 via small-volume nebulizer and 38,633 via metered-dose inhaler) were ordered. Overall, 4,012 medication treatments were missed (3.5% of the total), with variation by month ranging from 2.0% to 5.0%. The commonest reason for failure to administer the ordered bronchodilator treatment was the patient being out of the room at the time of the therapist's visit, which accounted for nearly one third of missed therapies. Next most common was the patient refusing treatment (24.6%), followed by the patient being unavailable because of ongoing activities or therapy (eg, physical therapy or a medical procedure). The least common reason was the respiratory therapist being called away to administer therapy to another patient (1.4%). CONCLUSIONS Overall, the frequency of missed bronchodilator treatments was relatively low in this series. The next steps include developing strategies to lower the frequency of missed treatments, so as to optimize the allocation of respiratory therapy services, and studying the clinical consequences of missed therapies.
منابع مشابه
Assessing the need for bronchodilator therapy: don't believe everything you hear.
The February 2003 issue of RESPIRATORY CARE1 contains the latest in a series of investigations of respiratory therapy practice by Dr James Stoller’s group at The Cleveland Clinic Foundation. In that latest contribution Dr Stoller et al examined the frequency and causes of missed bronchodilator treatments by a respiratory therapy service operating with respiratory therapy protocols. The investig...
متن کاملPhysician-ordered aerosol therapy versus respiratory therapist-driven aerosol protocol: the effect on resource utilization.
BACKGROUND The utilization of respiratory therapist (RT) driven protocols for single interventions, such as oxygen titration and bronchopulmonary hygiene, and protocols consisting of multiple interventions have been associated with improvements in resource utilization. Based on this, we started a quality improvement project to transition the delivery of respiratory care services from physician-...
متن کاملRole of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device (Ultibro, Breezhaler), often called QVA149, was first approved in 2013 in Japan and Europe. As of November 2014, more than 40 countries had approved this medication except for the USA. This is the first dual bronchodilator in one device. Now, the Breezhaler is the only device that can provi...
متن کاملFrequency, Type and Causes of Medication Errors in Pediatric Wards of Hospitals in Yazd, the Central of Iran
Background Medication errors are among the most common medical errors which are used as an indicator to assess patients’ safety in hospitals. Thereby the aim of this study was to investigate the frequency, type and causes of medication errors in children's ward at hospitals in Yazd- Iran. Materials and Methods This descriptive-analytical study was conducted during 6 months from Jan to Jun 2015....
متن کاملAsthma-like symptoms in a patient with rheumatoid arthritis and Adalimumab treatment.
After the introduction of anti-TNFα medication for treatment of autoimmune conditions, clinicians have investigated not only other possible uses for the drugs, but also less common side-effects and interactions with other pathologies. Despite some succes registered with Adalimumab as an antiinflammatory agent in severe asthma, there have been case reports of patients developing asthma or asthma...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Respiratory care
دوره 48 2 شماره
صفحات -
تاریخ انتشار 2003